Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing

Li Zhang
*University of Alabama at Birmingham*

*Et al.*

Let us know how access to this document benefits you.
Follow this and additional works at: [https://escholarship.umassmed.edu/oapubs](https://escholarship.umassmed.edu/oapubs)

Part of the Biochemistry Commons

Repository Citation

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in Open Access Publications by UMass Chan Authors by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.
Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing

Li Zhang, Ngoc-Tung Tran, Hairui Su, Rui Wang, Yuheng Lu, Haiping Tang, Sayura Aoyagi, Alan Guo, Alireza Khodadadi-Jamayran, Dewang Zhou, Kun Qian, Todd Hricik, Jocelyn Côté, Xiaosi Han, Wenping Zhou, Suparna Laha, Omar Abdel-Wahab, Ross L Levine, Glen Raffel, Yanyan Liu, Dongquan Chen, Haitao Li, Tim Townes, Hengbin Wang, Haiteng Deng, Yujun George Zheng, Christina Leslie, Minkui Luo, Xinyang Zhao

DOI: http://dx.doi.org/10.7554/eLife.07938
Cite as: eLife 2015;10.7554/eLife.07938

Received: 4 April 2015
Accepted: 16 November 2015
Published: 17 November 2015

This PDF is the version of the article that was accepted for publication after peer review. Fully formatted HTML, PDF, and XML versions will be made available after technical processing, editing, and proofing.

Stay current on the latest in life science and biomedical research from eLife.
Sign up for alerts at elife.elifesciences.org
Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing

Li Zhang1*, Ngoc-Tung Tran1*, Hairui Su1*, Rui Wang2, Yuheng Lu11, Haiping Tang4, Sayura Aoyagi10,
Ailan Guo10, Alireza Khodadadi-Jamayran1, Dewang Zhou1, Kun Qian5, Todd Hricik2, Jocelyn Côté6,
Xiaosi Han8, Wenping Zhou7, Suparna Laha9, Omar Abdel-Wahab3, Ross L. Levine3, Glen Raffel9,
Yanyan Liu7, Dongquan Chen12, Haitao Li4, Tim Townes1, Hengbin Wang1, Haiteng Deng4, Y. George
Zheng5, Christina Leslie11, Minkui Luo2, and Xinyang Zhao1

1. Department of Biochemistry and Molecular Genetics, UAB Stem Cell Institute, The University of
Alabama at Birmingham, Birmingham, AL 35294, USA.
2. Program of Molecular Pharmacology, Sloan Kettering Institute, New York, NY 10021, USA.
3. HOPP, Sloan Kettering Institute, New York, NY 10021, USA.
4. School of Life Sciences, Tsinghua University, Beijing, 100084 China.
5. Department of Pharmaceutical & Biomedical Sciences, The University of Georgia, Athens, GA
30602, USA
6. Department of Cellular and Molecular Medicine, University of Ottawa, 451 Smyth Road, Ottawa,
ON K1H 8M5, Canada.
7. Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University & Henan
Cancer Hospital, Zhengzhou 450008, China
8. Department of Neurology, Comprehensive Cancer Center, The University of Alabama at
Birmingham, Birmingham, AL 35294, USA.
9. Division of Hematology and Oncology, University of Massachusetts Medical School, 364
Plantation St, Worcester, MA 01605, USA.
10. Cell Signaling Inc. 3 Trask lane, Danvers, MA 01923, USA.
11. Computational Biology Program, Sloan Kettering Institute, New York, NY 10021, USA.
12. Division of Preventive Medicine, The University of Alabama at Birmingham, Birmingham, AL
35294, USA.

* These authors contribute equally.

Corresponding Author: Xinyang Zhao Ph.D. email: zhaox88@uab.edu, Tel: 205-975-5016 Fax: 205-975-
3335.

Keywords: PRMT1, RUNX1, c-MPL, GATA1, CNOT4, ubiquitylation, megakaryopoiesis, leukemia,
 hematopoiesis, RNA metabolism, RNA splicing

Major Organism: Human

Impact Statement: Inhibiting PRMT1 enzymatic activity promotes megakaryocyte differentiation via
RBM15-mediated RNA metabolism, which is dysregulated in hematological malignancies.
Abstract:

RBM15, an RNA binding protein, determines cell-fate specification of many tissues including blood. We demonstrate that RBM15 is methylated by protein arginine methyltransferase 1 (PRMT1) at residue R578 leading to its degradation via ubiquitylation by an E3 ligase (CNOT4). Overexpression of PRMT1 in acute megakaryocytic leukemia cell lines blocks megakaryocyte terminal differentiation by downregulation of RBM15 protein level. Restoring RBM15 protein level rescues megakaryocyte terminal differentiation blocked by PRMT1 overexpression. At the molecular level, RBM15 binds to pre-mRNA intronic regions of genes important for megakaryopoiesis such as GATA1, RUNX1, TAL1 and c-MPL. Furthermore, preferential binding of RBM15 to specific intronic regions recruits the splicing factor SF3B1 to the same sites for alternative splicing. Therefore, PRMT1 regulates alternative RNA splicing via reducing RBM15 protein concentration. Targeting PRMT1 may be a curative therapy to restore megakaryocyte differentiation for acute megakaryocytic leukemia.
**Introduction:**

RNA binding proteins control post-transcriptional processing such as alternative RNA splicing, polyadenylation and protein translation, which is a prevalent part of gene regulation in normal cell differentiation and in cancer development (Cabezas-Wallscheid et al., 2014; Chen et al., 2014; de Klerk and t Hoen, 2015; Shapiro et al., 2011). Arginine methylation of RNA binding proteins by protein arginine methyltransferases (PRMTs) regulates RNA splicing (Bedford and Clarke, 2009; Bezzi et al., 2013; Cheng et al., 2007; Sinha et al., 2010), subcellular localizations (Matsumoto et al., 2012; Nichols et al., 2000; Tradewell et al., 2012) as well as the binding affinity to RNA molecules (Rho et al., 2007). Nevertheless, the role of arginine methylation in regulating protein stability remains unknown. Here we demonstrate that an RNA binding protein, RBM15, is methylated by PRMT1, which triggers its ubiquitylation by an E3 ligase CNOT4.

RBM15 belongs to the Split Ends (Spen) family of proteins. Spen proteins are evolutionally conserved RNA binding proteins, which are involved in transcriptional regulation of NOTCH, WNT and MAPK signal transduction pathways (Chang et al., 2008; Chen and Rebay, 2000; Oswald et al., 2002; Rebay et al., 2000; Su et al., 2015). Recently SPEN and RBM15 have been shown to be essential for Xist-mediated X chromosome inactivation (Chu et al., 2015; McHugh et al., 2015; Minajigi et al., 2015; Moindrot et al., 2015; Monfort et al., 2015). Genetic studies in *Drosophila* have shown that *spen* is required for cell-fate decision during development (Kolodziej et al., 1995). *FPA*, the *RBM15* homolog in *Arabidopsis*, controls flowering via regulating alternative polyadenylation of antisense RNAs at the *FLC* locus (Hornyik et al., 2010). RBM15 is essential for the development of multiple tissues in mouse knockout models, in particular, for the maintenance of the homeostasis of long-term hematopoietic stem cells and for megakaryocyte (MK) and B cell differentiation (Niu et al., 2009; Raffel et al., 2009; Xiao et al., 2015). Furthermore, RBM15 is involved in the chromosome translocation t(1;22) which produces the RBM15-MKL1 fusion protein associated with acute megakaryoblastic leukemia (AMKL) (Ma et al., 2001; Mercher et al., 2001).
Spen proteins consist of two domains: an RNA binding domain and a SPOC (Spen Paralog and Ortholog C-terminal) domain. Previously, SPEN proteins such as RBM15 and SHARP have been shown to use the SPOC domains to recruit histone deacetylases for transcriptional regulation of Notch pathway and steroid receptor-dependent transcriptional regulation, and to recruit MLL complexes to promoters for histone H3K4 methylation (Ariyoshi and Schwabe, 2003; Lee and Skalnik, 2012; Ma et al., 2007; Oswald et al., 2002; Shi et al., 2001; Xiao et al., 2015). Additionally, RBM15 is also involved in RNA export (Uranishi et al., 2009; Zolotukhin et al., 2008; Zolotukhin et al., 2009). RBM15 resides mainly within nuclear RNA splicing speckles by confocal microscopy (Horiuchi et al., 2013b), suggesting that RBM15 is involved in RNA splicing. However, how spen proteins control cell differentiation is not described at molecular level.

In this report, we linked cellular differentiation to RBM15-regulated RNA metabolism using megakaryocyte differentiation as a model. We demonstrated that RBM15 binds to specific introns of pre-mRNA of genes such as RUNX1, GATA1 and TPOR (aka c-MPL or MPL), which play critical roles in megakaryocyte differentiation, and to 3'UTRs of genes involved in RNA splicing and metabolic regulation. Reducing RBM15 protein concentration by PRMT1-mediated methylation favors the production of the alternatively spliced isoforms: RUNX1a, GATA1s and c-MPL-exon9-, a truncated c-MPL isoform. We also found that RBM15 promotes megakaryocyte maturation in human primary cells. Therefore, PRMT1-RBM15 pathway fine-tunes cell differentiation via controlling the RBM15 protein concentration.

**Results**

**RBM15 is methylated by PRMT1**
In AMKL, MK differentiation is blocked. Gene expression data from AMKL patient samples (Bourquin et al., 2006) shows a higher PRMT1 expression level than other types of acute myeloid leukemia. Furthermore, high expression of PRMT1 is correlated with poor survival rate in acute myeloid leukemia (Figure 1-figure supplement 1). These clinical data strongly support that PRMT1 might be a key player in leukemogenesis. We applied bioorthogonal profiling of protein methylation (BPPM) technology (Figure 1-figure supplement 2) (Wang et al., 2011) to identify proteins methylated by PRMT1 in megakaryocytes. We found that RBM15 is methylated at R578 by mass spectrometry analysis (Figure 1-figure supplement 3A). Alignment of the RBM15 sequences covering the methylation site shows that the methylation site is conserved across diverse species (Figure 1A) and downstream of the RBM15 RNA binding domains (Figure 1-figure supplement 3B).

We validated that two generic antibodies against mono-methyl arginine proteins and against di-methyl arginine proteins (Cell Signaling Inc.), can recognize the methylated peptides from RBM15 (NP_073605) R578 region specifically in dot blots (Figure 1-figure supplement 3C&D). We observed that affinity purified Flag-tagged RBM15 protein is more efficiently methylated than the R578K mutant in western blots in transfected 293T cells (Figure 1B, compare lanes 1 and 2) as well as in leukemia cells (Figure 1-figure supplement 3E). Given that the R578 is the last arginine in the RDRDRD repeat, we mutated all three arginines, but we still detected low methylation background indicating other arginine residues not in the repeat are methylated (Figure 1-figure supplement 3F).

To determine whether PRMT1 is responsible, we overexpressed the two major isoforms of PRMT1 (V1 i.e. Q99873 and V2 i.e. Q99873-3) respectively in 293T cells together with wild type RBM15 (Figure 1C). Overexpressing either isoform enhanced the mono-methylation of RBM15 (Figure 1C, compare lanes 1, 2 and 3) and the V2 dimethylated RBM15 more effectively than the V1. Given that the V2 contains additional amino acids in the N terminal region relative to V1 (Figure 1D), it is striking that the PRMT1 V2 is primarily responsible for the dimethylation of RBM15 in vivo (Figure 1C).
In vitro methylation assays showed that the RBM15 peptide was dimethylated as efficiently as the histone H4 peptide without monomethylated peptides detected (Figure 1-figure supplement 3G). We then used purified Flag-RBM15 from 293T cells to conduct in vitro methylation assays. Only the wild type RBM15 protein but not the R578K mutant was effectively dimethylated by PRMT1 in vitro (Figure 1E). These results together with in vivo methylation data collectively argue that mono-methylated RBM15 is a transient intermediate in vivo.

To confirm that PRMT1 is responsible for in vivo methylation, we made MEG-01 stable cell lines expressing doxycycline-inducible shRNA against PRMT1. We detected the methylated form of RBM15 with both mono-methyl and dimethyl antibodies. Reducing the expression of PRMT1 decreased the methylation level of the endogenous RBM15 (Figure 1F). When the leukemia cells were treated with DB75 (a PRMT1 inhibitor) (Yan et al., 2014), RBM15 methylation was reduced (Figure 1G). The methylation of RBM15 was further confirmed by an antibody raised against dimethylated RBM15 at R578 (Figure 1-figure supplement 4). Therefore, we concluded that PRMT1 enzymatic activity is responsible for the methylation of RBM15 at R578. RBM15 might be methylated by other PRMTs and at other sites since some methylation signals especially the monomethylation signals are present despite PRMT1 knock-down or inhibition and in the R578K mutant respectively. Nevertheless the PRMT1-dependent R578 methylation forms the majority of dimethylated species.

RBM15 protein stability is determined by its methylation status

When RBM15 was co-expressed together with PRMT1, RBM15 protein level was reduced. Strikingly, the V2 isoform (detected by V2 specific antibody) caused a greater reduction of RBM15 protein level (Figure 2A), which coincided with the PRMT1 V2’s capability for RBM15 dimethylation (Figure 1C). To further confirm that methylation triggers protein degradation, we used non-specific methyltransferase inhibitors
Consistently, PRMT1 knockdown increased RBM15 protein level (Figure 2C, left panel) but not the RBM15 mRNA level (Figure 2C, right panel) in MEG-01 cells as well as in other leukemia cells (data not shown). Conversely, overexpression of PRMT1 V2 (Figure 2D, left panel) reduced RBM15 protein level. Given that the RBM15 mRNA levels in PRMT1 knockdown cells and in PRMT1 overexpressing cells were the same as in the control MEG-01 cells (Figure 2D middle and right panels), we concluded that PRMT1 controls RBM15 at protein level. Finally we observed that the specific knockdown of PRMT1 V2 resulted in higher RBM15 protein level (Figure 2E). Taken together, we concluded that the PRMT1 V2 enzymatic activity plays a major role in regulating the stability of the RBM15 protein.

When we co-expressed RBM15 R578K together with PRMT1 V2 protein in 293T cells, we found that the mutant protein remained stable regardless of overexpression of PRMT1 V2 (Figure 2F, compare lanes 4 and 2). Thus, methylation of RBM15 at R578 is the direct cause for protein degradation. To further determine whether RBM15 degradation is affected by methylation on R578, we compared the half-life of the wild type versus the mutant RBM15 proteins. The Flag-tagged RBM15 mutant has longer half-life compared with the wild type RBM15 (Figure 2G). Tag does not affect protein stability as the tagged RBM15 and endogenous RBM15 have similar half-life.

**RBM15 degradation is an ubiquitylation-mediated process**

We showed that the proteasome inhibitor MG132 stabilized the RBM15 protein, which indicates that the degradation is mediated by ubiquitylation (Figure 3A). To further confirm that the RBM15 protein is ubiquitylated, we used nickel beads to purify the poly-ubiquitylated form of RBM15 under denaturing conditions from 293T cells expressing the poly-histidine tagged ubiquitin and Flag-tagged RBM15 (Figure 3B).
To investigate whether methylation of RBM15 by PRMT1 is required for RBM15 ubiquitylation, we mutated the methylation site to lysine. Compared with the wild type RBM15 protein, significantly less R578K RBM15 protein was modified by ubiquitin (**Figure 3C** compare lanes 4 and 5,) when the respective plasmids were co-expressed in 293T cells. Thus, methylation on R578 for protein ubiquitylation is one major pathway for RBM15 degradation. To validate endogenous RBM15 is also ubiquitylated in a methylation-dependent manner, we treated the MEG-01 cells with PRMT1 inhibitor DB75. After DB75 treatment, less ubiquitylated RBM15 protein were observed (**Figure 3D**).

CNOT4 is the E3 ligase responsible for RBM15 ubiquitylation

PRMT1 has been shown to physically interact with the CCR4-NOT complex via the CAF1 (aka CNOT7) subunit for RNA export (Kerr et al., 2011; Robin-Lespinasse et al., 2007). Furthermore, CNOT4, a subunit of the CCR4-NOT complex, has been shown to be an E3 ligase (Albert et al., 2002). To examine whether CNOT4 might be responsible for ubiquitylation of RBM15, we co-expressed CNOT4 with RBM15 in 293T cells. Strikingly, when RBM15 was co-expressed with PRMT1 and CNOT4, RBM15 was more severely ubiquitylated than RBM15 expressed with PRMT1 or CNOT4 alone (**Figure 3E**). We also detected the interaction between PRMT1 and RBM15 wild type and mutant proteins in 293T cells (**Figure 3E** lanes 3, 4, and 7, 8). Moreover, only the wild type not the mutant RBM15 interacted with HA-tagged CNOT4 (**Figure 3E** lane 3, 4). In Figure 3E and Figure 3C, we showed that the RBM15 R578K, which cannot be methylated by PRMT1, had significantly less ubiquitylated RBM15 protein. This data strongly suggest that the methylation is required for subsequent ubiquitylation by the CNOT4 complex.

To further confirm that CNOT4 is the enzyme responsible for endogenous RBM15 ubiquitylation, we showed that CNOT4 knockdown (western blot in **Figure 3F** and real-time PCR in **Figure 3-figure supplement 2A**) increased the amount of endogenous RBM15 protein in MEG-01 cells (**Figure 3F**). When MEG-01 cells were treated with DB75, CNOT4 knockdown did not further stabilize the RBM15
protein (Figure 3F). These results confirm that methylation is required for the subsequent degradation of the RBM15 protein. We used CRISPR technology to knockout one allele of CNOT4 gene in 293T cells. We also found that removal of one allele of CNOT4 stabilized the endogenous RBM15 protein levels (Figure 3-figure supplement 2B&C).

We then purified the RBM15 and CNOT4 proteins (Figure 3-figure supplement 1) to do in vitro ubiquitylation assay. The methylated RBM15 protein (Flag-tagged) by PRMT1 was more efficiently ubiquitylated by CNOT4 than the purified RBM15 R578 in vitro (Figure 3G compare lane 5 to lane 3). Taken together, we demonstrated that the RBM15 protein stability is negatively regulated by PRMT1-mediated methylation at R578, and CNOT4 is an E3 ligase responsible for degrading the methylated RBM15. To understand further whether the methylation site on RBM15 is sufficient to bind to CNOT4 complex, we synthesized two RBM15 peptides covering the arginine methylation sites to pull-down CNOT4 from cell extract. The di-methylated peptide bound specifically to the CNOT4 protein (Figure 3H), which is agreeable with the coimmunoprecipitation data in Figure 3E showing that CNOT4 only interacted with wild type RBM15 proteins. This result implies that either CNOT4 or subunits in the CNOT4 complex directly interacts with RBM15 via the methylation mark.

PRMT1 V2 inhibits MK maturation via a methylation-ubiquitylation switch on RBM15

PRMT1 RNA levels were measured in isolated mouse long-term hematopoietic stem cells (LT-HSC), short-term hematopoietic stem cells (ST-HSC), progenitor cells and terminally differentiated lineages. PRMT1 expression level was the lowest in LT-HSC and higher especially in myeloid progenitor cells (Figure 4-figure supplement 1A-D). Megakaryocyte-erythrocyte progenitor (MEP) cells expressed the highest level of PRMT1. We also checked the expression of PRMT1 and RBM15 in human cells with HemaExplorer (Bagger et al., 2013). The expression profiles of PRMT1 and RBM15 in different lineages are shared between humans and mice (Figure 4-figure supplement 1E-G). The mRNA level of RBM15
does not change as dramatically as that of PRMT1 among different lineages, which implies that post-
transcriptional modification such as arginine methylation of RBM15 might contribute to the regulation of
RBM15 protein levels.

To understand the biological functions of PRMT1 in MK differentiation, we used PMA to stimulate MEG-
01 cells into mature MK cells (Ogura et al., 1988). Upon PMA stimulation, we observed upregulation of
the RBM15 protein within 12 hours and simultaneous down-regulation of the PRMT1 V2 protein (Figure
4A left and middle panels). During the incubation period, neither the RBM15 mRNA level (Figure 4A,
right panel) nor the total PRMT1 protein level (mainly V1 isoform) changed more than 1.5 folds,
nevertheless we found that RBM15 protein level was significantly increased. The methyl-RBM15 level
reduced coinciding with the decrease of the isoform V2 protein (detected by V2-specific antibody). Thus
we conclude the isoform V2 –mediated methylation is one mechanism for upregulating RBM15 protein
level, although we cannot rule out other possibilities such as enhanced protein translation. To assess
RBM15 effects on MK differentiation, we ectopically expressed the wild type and the R578K mutant
proteins in MEG-01 cells by retroviruses respectively. After stimulation with PMA for 7 days, more CD41+
cells (Figure 4B) as well as higher levels of polyploidy (Figure 4C) were detected. In comparison to wild
type RBM15, the RBM15 R578K generated more CD41+ cells, which may be explained by increased
RBM15 R578K stability (Figure 3).

However, the cell line differentiation system can only mimic certain aspects of normal megakaryopoiesis.
For example, we cannot detect CD42 in MEG-01 cells upon PMA stimulation. Therefore, we performed
MK differentiation assays with adult human CD34+ cells. Compared to the control, DB75 treated cells
produced a higher percentage of CD61+CD42+ mature MK cells (Figure 4D). Conversely, ectopic
expression of PRMT1 V2 in CD34+ cells promoted the generation of single positive CD61+ MK progenitor
cells but blocked MK cell maturation (Figure 4E). Like PRMT1 overexpression, knockdown of RBM15 by
shRNAs blocked MK maturation (Figure 4F, Figure 4-figure supplement 2), and overexpression of
both RBM15 and its mutant promoted the maturation of CD34+ cells (Figure 4G). Overexpression of RBM15 or RBM15 R578K rescued megakaryocyte differentiation in CD34+ cells expressing PRMT1 V2 (Figure 4H). Taken together, PRMT1 controls megakaryopoiesis via controlling RBM15 protein levels.

**RBM15 binds to pre-mRNA of genes in megakaryocyte differentiation**

To understand how RBM15 protein level controls megakaryocytic differentiation, we affinity purified RBM15-associated proteins from 293T cells, which express endogenous RBM15 protein. Mass spectrometry analysis showed that RBM15 was associated with ASH2 and WTAP, two known RBM15-bound proteins (Horiuchi et al., 2013a; Lee and Skalnik, 2012) as well as proteins involved in RNA splicing (Figure 7-source file 1), which is consistent with prior findings that RBM15 resides in nuclear splicing speckles (Horiuchi et al., 2013b). Thus, we reasoned that RBM15 might regulate alternative splicing. We performed RIP (RNA immunoprecipitation assay) under stringent wash conditions with an RBM15 antibody recognizing the N-terminal region, followed by RT-PCR to detect genes known important for megakaryocyte differentiation. We detected the bindings of RUNX1, GATA1 and c-MPL mRNAs with RBM15, while we did not detect that of control GAPDH mRNA (Figure 5A). Then we took an unbiased approach to identify global RBM15 target genes using RIP-seq. We have identified 1297 genes to which RBM15 binds directly (Figure 5-source file 1). 55% of RBM15 binding sites are in intronic regions, and 41% are in 3'UTR regions with the remainder in 5'UTRs and CDS elements (Figure 5B). Gene ontology pathway analysis showed RBM15 regulates genes involved in differentiation and signal transduction via binding to intronic regions whereas genes involved in RNA splicing and metabolic pathways via binding to 3'UTRs (Figure 5C&D). We found that overexpression of PRMT1 V1 and V2 isoforms as well as reducing the expression level of RBM15 enhanced mitochondria biogenesis in MEG-01 cells (Figure 5-figure supplement 3), which implies that PRMT1-RBM15 axis regulates metabolism. Among the RBM15 targeting genes with binding sites in introns are transcription factors known to be important for megakaryocyte differentiation: RUNX1, GATA1, and TAL1 (Figure 5-figure supplement 1,2). Although the transcription factor LEF1 has not yet been linked to MK differentiation, LEF1 has been
shown to interact with RUNX1 genetically and biochemically (Daga et al., 1996; Mayall et al., 1997; McNerney et al., 2013). RBM15 binding peaks on c-MPL pre-mRNA in the RIP-seq data (Figure 5-figure supplement 2).

To further investigate how RBM15 regulates alternative RNA splicing, we performed RNA-seq assays with RNA isolated from MEG-01 cells with or without RBM15 knockdown. The gene expression profile analysis showed that RBM15 knock-down alters metabolism and endoplasmic reticulum stress response pathways as well as proteins involved in chromatin assembly (Figure 5-source file 2). We then used two programs (DEXSeq and MISO) to detect the alterations of exon usage. DEXSeq detected 9704 differential exon usage events with P value lower than 0.05 and fold change higher than 1.2 fold. The MISO program detected 2027 differential exon usage events with Bayes factor higher than 2. RBM15 regulates differential exon usage in all eight categories in either directions (Figure 5 E&F). Significant exon usage changes of 156 genes in the RIP-seq group were detected by both programs (Figure 5-source file 3) including transcription factors RUNX1, GATA1, STAT5A, TAF9, TAL1, LEF1 and ZNF160 as well as chromatin remodeling factors such as macroH2A, DEK, BRD9, TLE3, NCOR1 and HDAC4. RUNX1, GATA1, STAT5A and TAL1(SCL) are well-studied transcription factors for their roles in megakaryocyte differentiation (Crispino, 2005; Olthof et al., 2008; Tijssen et al., 2011). Signal transduction genes important for hematopoiesis such as RPTOR and CDC42 (Kaushansky and Kaushansky, 2014) were found on the list as well. Therefore, RBM15 protein level may affect hematopoiesis via multiple pathways. At a molecular level, RBM15 not only affects alternative RNA splicing such as RUNX1, GATA1, TAL1, STAT5A, LEF1 but also affects UTR utilization (e.g. TAL1), mixed exon usage (e.g. CDC42) and intron retention (e.g. macroH2A) (Figure 5-figure supplement 4). The MISO program was used to analyze how GATA1 is alternatively spliced. After knocking down RBM15, we found skipping of exon 2 on GATA1 (Figure 5G) and validated our results by resolving GATA1 isoforms in an agarose gel (Figure 5H).

RBM15 regulates alternative splicing of genes important for megakaryocyte differentiation.
GATA1 has two different isoforms: full length GATA1 (GATA1fl), and short form GATA1 (GATA1s), which is generated by skipping the exon 2 (Rainis et al., 2003). In Down syndrome leukemia, GATA1fl mRNA translates the GATA1s protein when mutations on GATA1fl mRNA create an alternative translation start site. Using isoform specific probes targeting to the exon junctions of GATA1s and GATA1fl to perform real time PCR assays, we found that reducing RBM15 protein level favored the accumulation of GATA1s as the ratio of GATA1fl/GATA1s was reduced (Figure 6A top panel). Conversely, overexpression of RBM15 reversed the ratio of GATA1fl/GATA1s in favor of GATA1fl. The RBM15 R578K protein, which is more stable, altered the ratio more than the wild type RBM15. Furthermore, overexpression of V2 in MEG-01 cells reduced the ratio of GATA1fl to GATA1s similar to the effect of RBM15 knockdown. When we used inducible cell lines to knockdown PRMT1, we observed a higher ratio of GATA1fl/GATA1s like in cells overexpressing RBM15 (Figure 6A). To further probe the importance of PRMT1 enzymatic activity in alternative splicing, we used PRMT1 inhibitor DB75 to treat MEG-01 cells, CMK cells and CMY cells which all derived from AMKL leukemia patients. All three AMKL cell lines had higher GATA1fl/GATA1s ratio when treated with DB75 (Figure 6-figure supplement 1). Both isoforms of GATA1 can support megakaryocyte differentiation, but only GATA1s supports unrestricted proliferation due to losing the interaction with E2F1 (Li et al., 2000). Therefore, fine-tuning the ratio between two different GATA1 isoforms regulates the balance between proliferation and differentiation of megakaryocyte progenitors.

RUNX1 is required for megakaryocyte differentiation as shown in a conditional RUNX1 knockout mouse model (Ichikawa et al., 2004). Individual RUNX1 isoforms regulate hematopoiesis differently (Komeno et al., 2014b; Tsuzuki and Seto, 2012). RBM15 bound to RUNX1 pre-mRNA in intronic regions and in 3'UTR (Figure 5-figure supplement 2). The MISO program found that RUNX1 is alternatively spliced by skipping exon 6 which generates RUNX1-Exon 6 protein. Overexpression of RUNX1-Exon 6 in transgenic mice leads to reduced pool of hematopoietic stem cells (Komeno et al., 2014a)(Figure 5 figure supplement 4). Given that RBM15 binds to the 3'UTR in exon 8 as well as to intronic regions
flanking exon 7a, we investigated whether knockdown of RBM15 causes alternative 3’UTR usage to generate RUNX1a which uses exon7a’ 3’UTR. In RBM15 knock-down MEG-01 cells, the ratio between RUNX1a and RUNX1b,c switched in favor of RUNX1a. RUNX1a which lacks the transactivation domain acts as a dominant negative regulator to antagonize the function of RUNX1b,c (Ran et al., 2013a).

Increasing the amount of RUNX1a may interfere with the differentiation into mature megakaryocytes.

Consistent with RBM15 knockdown data, we showed that overexpression of RBM15 as well as knockdown of PRMT1 tilted the isoform balance toward RUNX1b,c. In agreement with the PRMT1 knockdown data, overexpression of PRMT1 V2 switched the ratio in favor of RUNX1a (Figure 6A middle panel).

The thrombopoietin receptor (TPOR, aka. c-MPL) is upregulated during megakaryocyte differentiation. c-MPL has at least 4 described isoforms in humans (Figure 6-figure supplement 2). Using reported primers (Li et al., 2000) to amplify cDNA from MEG-01 cells, we found an additional band on the PAGE gel, which was identified as an undescribed isoform lacking exon 9 (c-MPL-exon9-) through sequencing. The c-MPL-exon9- mRNA was predicted to yield a truncated protein (Figure 6-figure supplement 2).

Thus we designed specific primer spanning the junction between exon 8 and exon 10 to detect c-MPL-exon9- mRNA. We also used a pair of primers, the forward primer spanning exon 8 and exon 9 and reverse primer annealing to exon 9, to detect the full length MPL (i.e. c-MPL-exon 9+). The c-MPL-exon9-/c-MPL-exon9+ ratio was higher in favor of c-MPL-exon9- (Figure 6A, bottom panel) when RBM15 protein level is reduced. Furthermore, when RBM15 or RBM15 R578K was overexpressed, the ratio is down in favor of c-MPL-exon9+. Given that c-MPL exon9+ is required for MK differentiation, the data further support for the positive role of RBM15 at megakaryocyte maturation. All other isoforms with part of exon 9 or with both exon 9 and 10 missing were spliced in the same way by RBM15-PRMT1 pathway (Figure 6-figure supplement 3). Thus, RBM15 enhances the inclusion of exons to produce full-length functional c-MPL like in RUNX1’s case. Consistent with our data, mouse Rbm15 regulates c-Mpl alternative splicing in the same fashion (Xiao et al., 2014).
We monitored the isoform ratios using human adult CD34+ cells in pro-MK differentiation medium over a time course. We found that the GATA1fl/GATA1s ratio was increased, and the RUNX1a/RUNX1b,c ratio and c-MPL-exon9-/c-MPL-exon9+ ratio were decreased during the course of differentiation \((\text{Figure 6B})\). We observed that the isoform ratio changes in the DB75-treated CD34+ cells \((\text{Figure 6C})\) exactly like in the DB75-treated MEG-01 cells \((\text{Figure 6 figure supplement 1})\). Based on these data, we concluded that RBM15 regulates alternative RNA splicing of genes important for MK differentiation. By controlling the RBM15 protein dosage, PRMT1 thereby regulates MK differentiation.

**RBM15 controls alternative splicing via its interaction with SF3B1**

To understand the detailed mechanism of how RBM15 regulates alternative splicing, we identified RBM15-associated splicing factors such as SF3B1 and U2AF, known proteins in committed RNA splicing A complex that binds to branch point region \((\text{Figure 7-source file 1})\). Furthermore, we confirmed the interaction between SF3B1 and RBM15 by co-immunoprecipitation with anti-Flag antibody for Flag-tagged RBM15 proteins \((\text{Figure 7A})\) and with anti-RBM15 antibody \((\text{Figure 7B})\). To further confirm that PRMT1 enzymatic activity is important for alternative RNA splicing, we inhibited PRMT1 activity with DB75 or shPRMT1. The interaction between SF3B1 and RBM15 was subject to methylation regulation. One simple explanation is that RBM15 might recruit more SF3B1 because of more RBM15 and SF3B1 proteins available. It is also possible that methylation might be directly involved in RBM15 and SF3B1 interaction. Given that co-immunoprecipitation assays cannot distinguish the direct and indirect protein-protein interaction in a protein complex, RBM15’s interaction with SF3B1 only implies that RBM15 recruits the 3’RNA splicing complex. Since SF3B1 is often mutated in leukemia cells, we sequenced the SF3B1 gene in MEG-01 cells and confirmed that SF3B1 was not mutated in this cell line. Thus the interaction is between two wild type proteins.
From the RIP-seq data, we found that RBM15 was specifically associated with intronic region close to 5’end of the intron 1 of GATA1 (Figure 7C). We validated the RIP-seq data by real-time PCR with primer sets covering the GATA1 intron 1. Analysis of immunoprecipitated RNA associated with SF3B1 indicated that SF3B1 also preferentially bound to the same region that RBM15 bound to. Furthermore, with RBM15 knockdown, less SF3B1 was associated with GATA1 pre-mRNA (Figure 7D). On the other hand, GAPDH has similar level of SF3B1 binding to introns regardless of RBM15 expression level. Thus, RBM15 is responsible for recruiting SF3B1 to pre-mRNA molecules. In this case, RBM15 facilitates the inclusion of GATA1 exon 2. For c-MPL pre-mRNA, RBM15 preferentially bound to the intron 8 and intron 10 of the pre-mRNA molecules with two distinct peaks (Figure 7E left), while SF3B1 (Figure 7E right) did bind to regions between the two RBM15 bound peaks at higher level than other regions. When we used RBM15 knockdown MEG-01 cells to do SF3B1 RIP on c-MPL pre-mRNA, we found that SF3B1 binding was significantly reduced in RBM15 bound regions (Figure 7E right). In this case, RBM15 functions as a splicing enhancer for inclusion of exons 9 and 10. In aggregate, these data show that RBM15 is responsible for recruiting SF3B1 containing branch point recognition complex to introns, and methylation controls the RBM15 dosage thereby controls alternative RNA splicing (Figure 7F).

Discussion

We report here that PRMT1 V2 dimethylates RBM15 within the sequence (LYRD[me2]RDLY). Although the most common sequence for arginine methylation is arginine flanked by glycines, PRMT1 has been previously reported to methylate arginines in PGC1-α and in RUNX1 flanked by other amino acids (Teyssier et al., 2005; Zhao et al., 2008). Recent proteomics work further proves that the methylation motif can be very diverse (Guo et al., 2014). Since we can still detect a low level of mono-methylation signal after R578K mutation, we believe that the mono-methylation signals come from additional arginines methylated by PRMT1 or other arginine methyltransferases. Protein mono-methylation sites in general are redundant and prevalent which are catalyzed by multiple protein arginine methyltransferases (Dhar et al., 2013). Nevertheless, these potential sites are not involved in
methylation-mediated ubiquitylation. Another surprising result is that the V2 isoform, which contains additional amino acids on the N-terminus, primarily dimethylates RBM15 in vivo (Figure 1C). Data from PMA treated MEG-01 cells argue that the V2 isoform is more relevant to MK maturation (Figure 4A). Although it has been demonstrated that V1 and V2 have different substrate specificities in vivo (Goulet et al., 2007), RBM15 is the first V2 specific substrate identified. Of note, the V2 isoform only comprises less than 5% of total PRMT1 level, but V2 is mainly responsible for oncogenic activities in colon and breast cancers (Baldwin et al., 2012; Papadokostopoulou et al., 2009). We cannot completely exclude a role for V1 in RBM15 methylation due to the inability to knockdown V1 specifically. Because developing inhibitors specific for PRMT1 V2 isoform will potentially alleviate off-target effects, which remain a major impediment for developing anti-PRMT1 inhibitors, our data offers new clues on how to achieve V2 specific inhibition. RBM15 is involved in chromosome translocation t(1;22), which produces the fusion product RBM15-MKL1 (Ma et al., 2001; Mercher et al., 2001). Whether the fusion protein, which retains R578, is methylated by PRMT1 is still an unanswered question.

It was previously reported that methylation of a transcriptional coactivator p/CIP by PRMT4 or CARM1 leads to its degradation, however the mechanism was incomplete (Naeem et al., 2007). Here we report that PRMT1 methylation triggers protein degradation via ubiquitylation by the E3 ligase CNOT4. CNOT4 is loosely associated with the other subunits of CCR4-NOT complex (Lau et al., 2009). Apart from deadenylation activity of other CCR4-NOT complex, CNOT4 has been shown to ubiquitylate a histone demethylase Jhd2, which is responsible for erasing the histone H3K4 trimethylation marks in yeast (Mersman et al., 2009). Given that RBM15 interacts with histone methyltransferases complexes to maintain histone H3K4 methylation level (Lee and Skalnik, 2012; Xiao et al., 2015), our data provide new insights into a potential crosstalk between methyltransferases and demethylases.

Recently the E3 ligase WWP2 has been shown to recognize the methylated lysine in SOX2 through its HECT domain (Fang et al., 2014). Given that CNOT4 is within a large CCR4-NOT complex with 9
subunits, we have not determined which domain in CNOT4 or other subunits of CCR4-NOT complex recognizes the methylated RBM15. The peptide pull-down experiments strongly support that methylated region on RBM15 is sufficient for binding to CNOT4. Since we found that the RING domain on CNOT4 alone was not sufficient for binding to methylated RBM15 (data not shown), it is possible that more than one region on CNOT4 or other subunits in CCR4-NOT complex might interact with RBM15.

In order to investigate the biological significance of PRMT1-mediated methylation of RBM15, we analyzed the role of PRMT1-RBM15 axis in hematopoiesis. Normal MK differentiation can be divided into two phases: from hematopoietic stem cells to MK progenitor cells and from MK progenitor cells into mature polyploidy MK cells. There are examples that genes such as ARHGEF1 important (ARHGEF1,2 are in Figure 5-source file 1) for MK differentiation often play opposite roles at different phases (Gao et al., 2012; Smith et al., 2012). The number of MEP progenitor cells increases, while the polyploidy of mature megakaryocytes decreases in Rbm15 knockout mice (Niu et al., 2009). Consistent with this, RBM15 knockdown in human primary cells like Rbm15 knockdown in mice produces low percentage of mature megakaryocytes (Figure 4F). PRMT1 promotes the production of MEP cells, but PRMT1 has to be turned off to generate mature, polyploid CD41+/CD61+CD42+ MK cells. Because both PRMT1 and RBM15 are ubiquitously expressed in all tissues, PRMT1-RBM15 might regulate differentiation in the same fashion in other tissues such as cardiac tissue, spleen and placenta where RBM15 has been shown to be essential for development (Raffel et al., 2009).

According to the Oncomine database (www.oncomine.com), PRMT1 is highly expressed in acute myeloid and lymphoid leukemia (AML and ALL) as well as in solid tumors (Rhodes et al., 2007). PRMT1 accounts for 4% gene mutations, amplifications and deletions in solid tumors (see www.cbioportal.org) (Gao et al., 2013). The relevance of PRMT1 inhibition in cancer therapies is summarized in reviews (Greenblatt and Nimer, 2014; Yang and Bedford, 2013). The roles of PRMT1 in supporting cancer cell proliferation are shown in AML1-ETO and MLL-EEN initiated leukemia (Cheung et al., 2007; Shia et al.,
A PRMT1-mediated MK block may therefore be contributory to AMKL leukemogenesis. Apart from their functions in megakaryocyte differentiation, RUNX1, GATA1 and c-MPL as well as other epigenetic factors such as BRD4 found in this study are dysregulated in a broad spectrum of hematological malignancies as well as in solid tumors (Baratta et al., 2015; Crawford et al., 2008; Crispino, 2005; Harada et al., 2004; Pikman et al., 2006). Thus, dysregulation of PRMT1-RBM15 pathway might be a common mechanism in leukemia and solid tumors.

The role of RNA splicing is increasingly appreciated in hematological malignancies (Cazzola et al., 2013). The RNA splicing patterns vary widely from hematopoietic stem cells to progenitor cells in humans (Chen et al., 2014). Our studies offer mechanisms on how RNA splicing is regulated during hematopoiesis. RBM15 directly recruits the SF3B1 branch point recognition complex to introns. SF3B1 has been found to have mutations in myelodysplastic syndrome and in leukemia (Yoshida et al., 2011). Given that SF3B1 knockout mouse cannot mimic defects seen in myelodysplastic syndromes (Wang et al., 2014), mutations in SF3B1 are likely gain-of-function mutations. Whether altered interactions between RBM15 and SF3B1 mutants contribute to hematological malignancies warrants future study.

One direct consequence of RNA splicing is the altered concentration ratios between functional proteins and their alternatively spliced dominant negative counterparts. The physiological significance for multiple isoforms of c-MPL is to attenuate signaling from full-length c-MPL during megakaryocyte maturation. In transgenic mouse exclusively expressing full-length c-MPL, excessive production of platelets is observed (Tiedt et al., 2009). Abnormal expression of GATA1s and RUNX1a are associated with leukemia (Crispino, 2005; Liu et al., 2009). By controlling isoform ratios, HSCs fine-tune the lineage preference and the magnitude of lineage production during differentiation. This type of regulation is very important for HSCs to respond quickly to ever-changing environmental clues.
RBM15 by binding to introns flanking the alternatively spliced exons enhances the inclusion of the exons to produce full length c-MPL mRNA (Figure 7E). In the case of GATA1, RBM15 binds to intron 1 to recruit SF3B1 to the same location (Figure 7D). As a result, RBM15 enhances the inclusion of exon 2 to generate the GATA1fl mRNA (Figure 6A). RBM15 facilitate the production of more full length RUNX1b,c by skipping the exon which encodes RUNX1a. Knockdown RBM15 also facilitate the generation of RUNX1-exon6-. Based on our proteomic data, RBM15 binds to RNA binding proteins which are involved in RNA surveillance, transport and degradation (Figure 7-source file 1). Consistently, we also detected RBM15 association with matured mRNAs (Figure 5A). In addition, RBM15 associates with transcriptional elongation factors such as Tho2 and CTR9 besides its role in transcription initiation by positively regulating histone H3K4 methylation (Xiao et al., 2015). We speculate that RBM15 participates in regulating the whole life cycle of a messenger RNA. This is reminiscent of the functions of CCR4-NOT complex (Miller and Reese, 2012). RBM15 has been shown to be part of RBM20-mediated RNA splicing network in cardiomyocytes (Maatz et al., 2014; Raffel et al., 2009). Thus, RBM15 is involved in development of other tissues in addition to hematopoiesis. Further experiments to define the specificity and affinity of RBM15 binding sequences will help us to understand the mechanisms of alternative splicing mediated by RBM15.

Apart from binding to introns, RBM15 binds to 3'UTR of metabolic enzymes, splicing factors as well as a few long noncoding RNA molecules and microRNAs (Figure 5-source file 2). Given that splicing factors can be involved in alternative RNA polyadenylation and RNA export, it is not surprising that RBM15 binds to 3'UTRs for alternative RNA polyadenylation, export as well as for RNA splicing (Castelo-Branco et al., 2004; Kyburz et al., 2006). Analysis by the MISO program indicates that RBM15 regulates alternative RNA splicing of genes such as HK1 by binding to 3'UTR. In the future, deeper sequencing of RNA samples and performing high resolution PAR-CLIP assays (Hafner et al., 2010) with RBM15 antibodies will further define the RBM15-mediated RNA metabolism.
In summary, our findings demonstrated a new role for PRMT1 in regulating RNA metabolism. Given that both RBM15 and PRMT1 are evolutionarily conserved proteins from plants to mammals, our studies on the PRMT1-RBM15 pathway offer mechanistic insights into how RBM15 may regulate cell fate decision in multi-cellular organisms at post-transcriptional levels.

**Methods**

**Using BPPM technology to profile PRMT1 methylated proteins**

To reveal proteome-wide substrates of protein methyltransferases such as PRMT1 in the context of complex cellular components, we took advantage of the emerging Bioorthogonal Profiling of Protein Methylation (BPPM) technology (Luo, 2012; Wang and Luo, 2013). In BPPM, designated methyltransferases are engineered to process sulfonium-alkyl SAM analogues as alternative cofactors and thus transfer the distinct sulfonium alkyl handles to substrates (*Figure 1-figure supplement 2A*).

Because the alkyl handles contain a terminal-alkyne for the azide-alkyne Huisgen cycloaddition (the click reaction), we can then couple the chemical moiety with a biotin-containing azide probe for amenable target enrichment and characterization. With the previously-identified Y39F-M48G PRMT1 mutant and the matched 4-propargyloxy-but-2-enyl SAM (Pob-SAM) as BPPM reagents (Wang et al., 2011), RBM15 in the context of Meg-01 cells was readily labeled by the enzyme-cofactor pair, modified by a biotin-containing azide probe, and enriched by streptavidin beads (*Figure 1-figure supplement 2B*). As the negative control, the label efficiency dropped significantly in the absence of the Y39F-M48G PRMT1 variant. The tagged proteins were subsequently purified with streptavidin beads for mass spectrometry analysis. RBM15 was identified among the methylated proteins. We verified the mass spectrometry data with direct western blot with RBM15 antibody against biotinylated proteins (*Figure 1-figure supplement 2C*). To further map the RBM15 methylation sites, Flag tagged RBM15 protein was purified from transient transfected 293T cells for tandem mass spectrometry analysis. A mono-methylation site was found at R578, which lies between the RNA binding domain and the SPOC domain (*Figure 1-figure supplement 3A*).
**Plasmids:**

The human RBM15 cDNA in pCDNA3 vector was kindly provided by Dr. Barbara Felber (NIH). The nucleotide sequences of all constructs were verified by sequencing. The retrovirus expression vector Migr1 was used to overexpress RBM15 and its mutant. pTripZ (Openbiosystems) was used to overexpress the PRMT1-V1 and PRMT1-V2 proteins by replacing RFP with PRMT1-V1 or PRMT1-V2 cDNA. The lentivirus expressing shRNA against PRMT1, RBM15, and CNOT4 were purchased from Openbiosystems (ThermoScientific Inc.). The sequences are available in *Supplementary file 1*. pRS and pRS-shPRMT1-V2 plasmids were reported previously (Baldwin et al., 2012).

**Viral production and transduction**

For virus production, 293T cells were cotransfected with retroviral or lentiviral plasmids with helper plasmids as described (Vu et al., 2013). Cells stably expressing PRMT1-V1 and PRMT1-V2 or knockdown RBM15 or PRMT1 were selected with 5 µg/ml puromycin, and GFP-positive cells stably expressing Flag-RBM15 and Flag-RBM15-R were sorted on a FACSria cell sorter. BD FACS LSRFortessa was used to do FACS analysis.

**New isoform of c-MPL**

The gene bank number for this new c-MPL isoform is KF964490.

**Cell culture**

HEK293T cells were cultured in DMEM supplemented with 10% FBS and transient transfected by lipofectamine 2000 (Invitrogen, Grand Island, USA). The pcDNA3 empty vectors were added to all transfections to balance total DNA. The human leukemic cell line MEG-01 was cultured in RPMI1640 medium containing 10% FBS with 100U/ml penicillin and 100µg/ml streptomycin. The generic methyltransferase inhibitors: Adox (adenosine, periodate oxidized, Sigma, #7154) and MTA (5'-Deoxy-5'-(methylthio) adenosine, Sigma, #D5011) were purchased from Sigma, St. Louis, USA. PMA (20nM) was
added to stimulate Meg-01 cells to differentiate into megakaryocytes. The differentiated cells were labeled with anti-CD41 antibody and CD42 antibody (BD) and analyzed by FACS Fortessa machine.

**Coimmunoprecipitation and Immunoblot analysis**

Transfected 293T cells from 10-cm dish were lysed in 1 ml of lysis buffer (20mM Hepes, pH 7.9, 150 mM NaCl, 1mM MgCl₂, 1% NP40, 10 mM NaF, 0.2 mM NaVO₄, 10 mM β-glycerol phosphate) with freshly added DTT (1 mM) and a proteinase inhibitor cocktail (Roche, Indianapolis, USA). The cells were incubated for 30 minutes on ice and sonicated with a Bioruptor Sonicator (Diagenode, Denville, USA). The extracts were cleared by centrifugation at 12,000×g for 15 min at 4 °C. Immunoprecipitations were performed at 4°C in lysis buffer in the presence of RNaseA (10µg/ml) using indicated antibody and 50 µl of 50% (V/V) slurry of Protein A agarose (Roche, Indianapolis, USA) or anti-Flag M2 agarose (Sigma, St. Louis, USA) for 4 hours. The precipitates were extensively washed and resuspended in 2×SDS-PAGE sample buffer directly. The immunopurified protein and cell lysates were resolved by 10% SDS-PAGE and transferred to PVDF membranes (Millipore, Billerica, USA) for western blot assays. The proteins were visualized by the Immobilon Western Chemiluminescent horseradish peroxidase substrate detection kit (Millipore). PRMT1-V2 specific antibody was reported (Baldwin et al., 2012). The other antibodies used were commercially available, including anti-Flag M2 Ab (#F1804, Sigma), RBM15 monoclonal antibody (#66059-1-1g, Proteintech, Chicago), RBM15 polyclonal antibody (#: 10587-1-AP, Proteintech, Chicago), PRMT1 (#07404, Upstate Biotechnology), SF3B1 (#PA5-19679, Thermo Scientific), Ub (#U5397, Sigma) and GAPDH (#MA5-15738, Thermo Scientific, Waltham).

**Detection of in vivo Ubiquitylation**

HEK293T cells transfected with Flag-RBM15 and His-ubiquitin expression plasmids for 40 hours were treated with 10 µM MG132 for 6 hours before harvesting. Cells were lysed in buffer A (6 M guanidine-HCl, 0.1 M Na₂HPO₄/NaH₂PO₄, pH 7.5, 10 mM imidazole) at 4°C for 15 minutes. The lysate was sonicated for 20 cycles in Bioruptor Sonicator. After cleaned by centrifugation at 12,000g for 30 minutes at 4°C, the supernatant was incubated with Ni²⁺-NTA beads (QIAGEN, Valencia, USA) for 3 hours at
room temperature. The beads were sequentially washed with buffer A, buffer B (1.5 M guanidine-HCl, 25 mM Na₂HPO₄/NaH₂PO₄, 20 mM Tris-Cl [pH 6.8], 17.5 mM imidazole), and buffer C (25 mM Tris-Cl [pH 6.8], 20 mM imidazole). The ubiquitin-conjugated proteins were boiled in 2×SDS-PAGE loading buffer containing 200 mM imidazole and subjected to immunoblot analysis.

Real-time PCR Assay

Total RNA was prepared using RNeasy plus Kit (QIAGEN). cDNA was generated by the Verso cDNA synthesis Kit (Thermo Scientific) with random hexamer primers. Real-time PCR assays were performed with Absolute Blue qPCR SYBR green Mix (Thermo Scientific) or Taqman Universal Master Mix II (Applied Biosystems, for GATA1-FL and GATA1-S) on a ViiA 7 system (Applied Biosystems). Primers are listed in Supplementary file 2. GAPDH was used as an internal control for normalization. Relative expression level was calculated by ∆(∆ct) method and all results were expressed as mean values± standard errors from at least 3 independent experiments.

GATA1 isoforms can be detected by regular PCR reactions with the primers: GATA1 Ex1 F : ATCACACTGAGCTTGCCACA, GATA1 Ex3 R: AGCTTGGGAGAGGAATAGGC in Figure 5H.

Identification of protein methylation by mass spectrometry

For identification of methylation sites of targeted proteins, samples were separated by 10% of SDS PAGE. The gel band were excised from the gel, reduced with 10 mM DTT and alkylated with 55 mM iodoacetamide. Then in-gel digestion was carried out with the sequencing grade modified trypsin (Promega, Fitchburg, WI) in 50 mM ammonium bicarbonate at 37 °C overnight. The peptides were extracted twice with 1% trifluoroacetic acid in 50% acetonitrile aqueous solution for 30 min. The extractions were then centrifuged in a speedvac to reduce the volume.
For LC-MS/MS analysis, the digested product was separated by a 60 min gradient elution at a flow rate of 0.30 µL/min using an UltiMate 3000 RSLCnano System (Thermo Scientific, USA) which was directly interfaced with a Thermo Q Exactive benchtop mass spectrometer. The analytical column was a homemade fused silica capillary column (75 µm ID, 150 mm length; Upchurch, Oak Harbor, WA) packed with C-18 resin (300 Å, 5 µm, Varian, Lexington, MA). Mobile phase A consisted of 0.1% formic acid, and mobile phase B consisted of 100% acetonitrile and 0.1% formic acid. The mass spectrometer was operated in the data-dependent acquisition mode using the Xcalibur 2.2.0 software and there is a single full-scan mass spectrum in the Orbitrap (400-1800 m/z, 70,000 resolution) followed by 8 MS/MS scans under the higher energy collision dissociation (HCD). The MS/MS spectra from each LC-MS/MS run were searched against the selected database using an in-house Mascot or Proteome Discovery searching algorithm.

**Peptide pulldown assay**

The peptide pulldown method is published before (Vu et al., 2013). Briefly, two peptides (Biotin-LLYRDRDRME2ADLYPDSDWV and Biotin-LLYRDRDRDLYPDSDWV) with or without methylation on R578 were synthesized. Biotin was added for binding to streptavidin beads. 200 µl of the whole cell extract (10mg/ml in H lysis buffer) prepared as mentioned in co-immunoprecipitation assays was used to incubate with peptides (at final concentration of 1 µM) overnight at 4°C. The beads were washed with wash buffer (300mM NaCl, 1mM DTT, 20mM Tris pH 7.4 and 0.1% NP40) five times. Protein bound to the beads were boiled in SDS sample buffer and resolved in 10% SDS PAGE.

**Survival analysis:**

RNA-seq data of 200 acute myeloid leukemia (AML) samples were downloaded from the Cancer Genome Atlas (TCGA). The PRMT1 expression levels were used for survival analysis using Kaplan Meier (K-M) curves and log-rank tests. Samples with available clinical outcomes (survival month, n=103) data were included in the analysis. Logarithm 2-based transformations of each gene were performed prior to any analysis. Significant association was determined at 5% type I error level.
Two guide RNAs were designed to target exon 2 of human CNOT4 at two different sites using the CRISPR design tool (Zhang’s lab) (Ran et al., 2013b). The distance between target sites is roughly 100bp. Two gRNAs were cloned into pX330 vector, and transient transfected into 293T cells. Single cells were selected by serial dilution. Single cell colonies were screened for internal deletion by PCR using 2 primers: F: TTCCCCTAAATGTGTTATGATGA; R : CCAGTCAGGTGTTCTTTCCA. Guide RNA sequences: (1) CACCG GGATGTCATGTCCTCAGCGT; (2) CACCGGTGGATGCCAAAGTGTGCGT.

Developing anti-peptide antibody against RBM15

RBM15 N-terminal sequence (Acetyl-RTAGRDPVPRRSRPRWRRAVPLC) was used to develop rabbit polyclonal antibody against RBM15 by GeneMed Synthesis Inc. (St. Antonio, Texas) for RNA immunoprecipitation assay.

RNA immunoprecipitation assay

Ten millions of MEG-01 cells grown at the exponential phase were cross-linked by 1% of formaldehyde in 37°C incubator for 10 minutes. Cells were washed twice with ice-cold PBS, lysed in H-lysis buffer (20mM HEPES pH7.9, 300mM NaCl, 1mM MgCl2, 1% NP40, NaF 10mM, 0.2mM NaVO4, 10mM β-glycerol phosphate, 5% glycerol, 1mM DTT, 40 U/ml RNaseOUT, and proteinase inhibitors), and then sonicated by Bioruptor (Diagenode) to fragments with average sizes of 200bp (DNA) for 30 minutes at 4°C. After the lysate was spun down, the supernatant was incubated with RBM15 antibody overnight at 4°C. Beads were washed five times with stringent buffer (50mM Tris pH7.5, 1M NaCl, 1mM EDTA, 0.1%SDS, 1% Na Deoxycholate, 1M Urea, and 1% NP40), and once with TE buffer (10mM Tris pH 7.9, 1mM EDTA). Immunoprecipitated RNA were eluted by incubating with 150μl RIP elution buffer (50mM Tris-Cl pH 7.9, 5mM EDTA, 1% SDS, 200mM NaCl and 267 μg/ml of proteinase K) for 1h at 45°C. Genomic DNA was removed by DnaseI Turbo (Ambion). RNA was extracted by Trizol (Invitrogen) and...
cDNA was synthesized with random priming (Thermo Verso cDNA synthesis kit). The cDNA was analyzed by qRT-PCR.

We did two biological replicates for RIP-seq experiments with anti-RBM15 antibody and normal IgG respectively. The RNA was converted into cDNA using SureSelect single strand RNA selection kit (Illumina) and sequenced with Illumina 2000 sequencer.

Primary cell culture for megakaryocyte differentiation

G-CSF mobilized peripheral human blood cells were used to purify CD34+ cells. These CD34+ cells were spinfected with lentiviruses and grown in basic cytokine mix (100ng/ml of SCF, 100ng/ml FLt3 ligand, 50ng/ml of IL-6 and 20ng/ml of TPO) with IMDM medium plus 20% BIT (Stem cell Technology). For megakaryocyte differentiation, we cultured the CD34+ cells with 50ng/ml TPO and 2ng/ml of SCF. The maturation of MK cells was assessed for the percentage of CD41+CD42+ or CD61+CD42+ populations as well as the percentage of polyploidy with PI staining by FACS analysis.

Computational analysis of RIP-seq data and RNA-seq data

We first trimmed adaptor sequences and low quality bases from paired end RIP sequencing reads using Trimmomatic (Bolger et al., 2014). Processed reads were then mapped to hg19 genome with the STAR (Dobin et al., 2013) aligner. RIP reads from all samples were summarized into read coverage profiles on all chromosomes, and peaks were identified with a custom algorithm (Loeb et al., 2012) by convolving the read coverage signal with the second derivative of a Gaussian filter (bandwidth = 300). For each peak, we used DESeq (Anders and Huber, 2010) to test if there was significant difference in read counts within the peak region between RBM15 samples and control samples after correcting for library size differences. 1515 peaks with more reads in RBM15 samples and FDR < 5% were defined as significant RBM15 binding sites. Each peak was annotated with information including gene name and region (i.e. intron, 3’UTR, 5’UTR, CDS) according to the overlapping RefSeq transcript.
We did 100bp pair ends sequencing for the RNA samples. More than 100 million reads per sample were collected. All the reads were mapped to the human reference genome (GRCh37/hg19) using STAR with a Gene Transfer File (GTF version GRCh37.70). The mean insert sizes and the standard deviations were calculated using Picard-tools (v1.126) (http://broadinstitute.github.io/picard/).

Differential exon usage was calculated by DEXSeq (Anders et al., 2012) and an even-based analysis using MISO (Katz et al., 2010) to measure the abundance of event types: skipped exon (SE), mixed exon usage (MXE), alternative first exon (AFE), alternative last exon (ALE), alternative 5’ or 3’ splicing sites (A5SS or A3SS) and tandem 3’UTR use (T3UTR). The Read Per Million (RPM) normalized BigWig files were generated using BEDTools (v2.17.0) and bedGraphToBigWig tool (v4). And all the downstream statistical analyses and generating plots were performed in R (v3.1.1) (http://www.r-project.org/). All the RNA-seq and RIP-seq data were deposited in NIH (GSE73893).

In vitro ubiquitylation assay

In vitro ubiquitination assay was performed essentially as described (Wang et al., 2004). Briefly, RBM15 or RBM15 R578K with or without PRMT1-mediated methylation were incubated with HA-CNOT4 in 32.5 μl reaction mixture containing 50 mM Tris (pH7.5), 5 mM MgCl2, 2 mM NaF, 2 mM ATP, 10 mM Okadaic acid, 0.6 M DTT, 0.1 mg E1, 0.2 mg UBCH5C and1 mg recombinant ubiquitin (Sigma). Reactions were carried out for 1 hour at 37°C before stopping with SDS sample loading buffer and resolving by 8% SDS-PAGE. Ubiquitination was detected by Western blot with anti-Flag antibody.

Acknowledgements

We would like to thank Drs. Nouria Hernandez (UNIL), Stephen Nimer (UMCCC), Michael Crowley, Chris Klug, Kevin Pawlik, Ching-Yi Chen, William Placzek, Camelia Iancu-Rubin (MSH) for help; Dr. John Crispino (NWU), Thomas Mercher (INSERM, Paris) and Dr. Barbara Felber (NIH) for reagents. YL is supported by CNSF (#81270570). We would like to thank the UAB Comprehensive Flow Cytometry Core as part of RDCC (P30AR048311 and P30AI027767) for technical support.
Additional information

Competing Interests:

All authors declare that competing interests exist.

Funding

| The University of Alabama at Birmingham | New Investigator Start-up | Xinyang Zhao |
| China National Science Foundation | 81270570 | Yanyan Liu |

Author contributions

NTT, LZ, HS, Conception and design, Acquisition of data, Analysis and Interpretation of data; RW, HT, Acquisition of data; YL, analysis and interpretation of data; AG, SA, AK, DZ, KQ, TD, XH, SL, contributed unpublished data and reagents; JC contributed unpublished data and reagents, revising the article; OAW, RL, Contributed unpublished data and reagents, analysis and interpretation of data; GR, revising the article, and analysis and interpretation of data; YL, Contributed unpublished data and reagents, analysis and interpretation of data; DC, Acquisition of data, Analysis and interpretation of data; HL, TT, Contributed unpublished data and reagents, analysis and interpretation of data; HW, HD, Acquisition of data, Analysis and interpretation of data; YGZ, Contributed unpublished data and reagents, Analysis and interpretation of data; ML, XZ, Conception and design, Acquisition of data, Analysis and Interpretation of data; Drafting and revising the article.
**Figure legends**

**Figure 1.** RBM15 is methylated by PRMT1 at R578 in mammalian cells. (A) Alignment of RBM15 sequences among different species shows R578 within a conserved protein region. (B) RBM15-Flag and its mutant (R578K), affinity purified with anti-Flag antibody from transfected 293T cells, were detected by western blot (WB) with anti-monomethyl arginine antibody. (C) Flag-tagged RBM15 was affinity purified by Flag antibody for WB with two generic antibodies against mono-methyl arginine and dimethyl arginine respectively. The 293T cells overexpressing wild type RBM15-Flag protein with PRMT1 V2 (lane 2) and V1 (lane 3) respectively were treated with 20nM MG132 for 6 hours before harvesting. (D) The differences between N terminal sequences of PRMT1 V1 and V2 isoforms. (E) *In vitro* methylation assays. Affinity purified RBM15 protein was methylated by incubation with purified HA-PRMT1 and 0.15 mM of S-adenosyl-methionine at 30°C for four hours. The methylated RBM15 was detected by anti-dimethyl arginine antibody in WB. (F) RBM15 was immunoprecipitated with a mouse monoclonal anti-RBM15 antibody from whole cell extract prepared from a MEG-01 stable cell line expressing inducible shRNA against PRMT1. Normal IgG was used as immunoprecipitation controls. The immunoprecipitated RBM15 was detected by WB with antibodies against mono-methyl arginine (mono-R100) and asymmetrical dimethyl arginine (D4H5) respectively. As controls, we did WB with anti-PRMT5 and anti-PRMT4 antibodies. (G) Detection of methylated RBM15 in MEG-01 stable cell lines expressing Flag-RBM15 and R578K mutant proteins respectively after a PRMT1 inhibitor (DB75) treatment for 24 h. RBM15 is affinity purified by anti-Flag antibody and detected by WB with mono-methyl arginine antibody and dimethyl arginine antibody.

**Figure 1-figure supplement 1.** PRMT1 is overexpressed in AMKL leukemia and associated with short survival rate in AML.

**Figure 1-figure supplement 2.** RBM15 is discovered as a PRMT1 substrate via BPPM.

**Figure 1-figure supplement 3.** Mapping the methylation site for RBM15.
**Figure 1-figure supplement 4.** RBM15 methylation status is further confirmed by a methyl-RBM15 antibody.

**Figure 2.** PRMT1 V2 isoform destabilizes RBM15 via methylation. (A) WB for RBM15 in 293T cells overexpressing PRMT1 V1 and V2 respectively. PRMT1 V2 was detected by anti-V2 specific antibody (PRMT1 V2). PRMT1 V1 and V2 were detected by an antibody for all isoforms (labeled as PRMT1). (B) The level of the RBM15 protein as detected by WB in MEG-01 cells treated with methyltransferase inhibitors (Adox and MTA mix) or DB75. (C) RBM15 protein level was measured by WB in MEG-01 cells with two doxycycline-inducible shRNA against PRMT1 (on the left). In the middle and right sides are real time PCR results to show the mRNA levels of total amount of PRMT1, PRMT1 V2, and RBM15 in shPRMT1#1 stable MEG-01 cell line (middle) and in shPRMT1#2 stable MEG-01 cells (right). All data are presented as mean ± SD from three independent experiments. (D) RBM15 protein level was measured by WB in MEG-01 cells induced by doxycycline to express PRMT1 V2 isoform. On the right are the real-time PCR charts for PRMT1 V2 and RBM15 mRNA levels. Data are presented as mean ± SD from three independent experiments. (E) RBM15 protein level was accessed by WB in a MEG-01 stable cell line expressing shRNA against V2. The names of antibodies are listed on right. The pRS vector retrovirus infected MEG-01 cells were used as control. (F) WB with anti-Flag antibody to detect the protein levels of RBM15 wild type and R578K mutant proteins in 293T cells overexpressing PRMT1 V2 and RBM15 proteins. (G) The half-life of the RBM15 proteins in MEG-01 cells, and stable cell lines overexpressing Flag tagged RBM15 and RBM15 R578K were assessed by WB respectively. Cyclohemixide were added to stop protein synthesis 30 minutes before harvesting cells as the 0 time point. The half-life curves were plotted by GraphPad Prism 6.

**Figure 3.** The RBM15 is ubiquitylated in a methylation-dependent manner. (A) Western blots for the RBM15 protein from MEG-01 cells treated with the proteasome inhibitor MG132. (B) The ubiquitylated RBM15-Flag was detected by anti-Flag antibody. The poly-ubiquitylated RBM15 was purified with nickel beads under denaturing conditions (6M of guanidine-HCl) from 293T cells expressing RBM15-Flag and
poly-histidine-tagged ubiquitin. (C) The ubiquitylated RBM15 was measured by anti-ubiquitin antibody after affinity purified with Flag antibody from MG132 treated 293T cells expressing RBM15-Flag or R578K-Flag and ubiquitin. (D) IP-western blot for poly-ubiquitylated RBM15 in DB75 treated MEG-01 cells. The endogenous RBM15 protein was immunoprecipitated by anti-RBM15 antibody and then blotted with anti-ubiquitin antibody and anti-RBM15 antibody. (E) The ubiquitylated RBM15 was detected by anti-Ub antibody after RBM15-Flag as well as its mutant was affinity purified from 293T cells transfected with combinations of plasmids shown above the gel. CNOT4 was detected via its HA tag. (F) WB to detect RBM15 protein levels in two MEG-01 cell lines expressing two different shCNOT4 respectively. PRMT1 inhibitor (DB75) was used to treat the cells expressing shCNOT4 RNAs. The efficiency of shCNOT4 knockdown was checked by real-time PCR. (G) In vitro ubiquitylation assays with CNOT4 and RBM15. Purified PRMT1 was added to methylate RBM15 in vitro in lanes 5 and 6 first before incubating with CNOT4 for in vitro ubiquitylation assays. All components were affinity purified from 293T cells. The ubiquitylated RBM15-Flag was detected by WB with anti-Flag antibody. (H) CNOT4 from MEG-01 whole cell extract was pulled down with methylated and nonmethylated peptides of RBM15. CNOT4 was detected by WB with anti-CNOT4 antibody.

Figure 3-figure supplement 1. Purified proteins used in vitro methylation and ubiquitylation assays.

Figure 3-figure supplement 2. The efficiency of CNOT4 knockdowns.

Figure 4. PRMT1 controls the protein level of RBM15 in megakaryocyte maturation. (A) WB to measure the protein levels in MEG-01 cells stimulated to maturation by PMA. The left panel (WB results) showed the protein levels by antibodies against GAPDH, RBM15, Methyl-RBM15, PRMT1 with a PRMT1 antibody against all isoforms and PRMT1 V2 with specific V2 antibody during the course of maturation. The middle panel shows the quantitation of the protein bands in the western blots on the left normalized to GAPDH. The right panel showed the decrease of PRMT1 V2 by real time PCR during maturation with GAPDH mRNA as an internal control. Real-time PCR data were presented as means ± SD from three independent experiments. (B) Histograms of CD41⁺ cells on PMA treated MEG-01 cells overexpressing
RBM15 and RBM15R578K mutant proteins respectively on day 3. The percentage of CD41+ cells was calculated according to matched antibody isotype control. Three independent experiments were done with statistics shown on the left. P*** <0.001, P** <0.01. (C) FACS analysis of the polyploid status of PMA treated cells overexpressing RBM15 and R578K mutant proteins by PI staining. Vector: lentivirus vector. P*** <0.001. (D) The matured MK cells were measured by CD61+CD42+. Human adult CD34+ cells in pro-megakaryocyte differentiation medium were treated with DB75 for three days. Three independent experiments were done with P*< 0.05. (E) Human adult CD34+ cells were infected with lentivirus expressing PRMT1 V2 or lentivirus vector and grown in pro-MK differentiation medium for five days. Three independent experiments were done with P***<0.001. (F) Human adult CD34+ cells were infected with two lentiviruses expressing shRNAs against RBM15 and grown in pro-MK differentiation medium. Three biological replicates were used for P value. P** <0.01. (G) Human adult CD34+ cells were infected with lentiviruses expressing RBM15 or R578K proteins and grown in pro-MK differentiation medium for five days. Three independent experiments were done with P**<0.01. (H) Human adult CD34+ cells were infected with lentiviruses expressing RBM15 or R578K together with a lentivirus expressing PRMT1 V2 and grown in pro-MK differentiation medium. Three biological replicates were used for P value. P**<0.01.

Figure 4-figure supplement 1. Relative expression levels of PRMT1 isoforms and RBM15 in different hematopoietic lineages derived from mouse and human.

Figure 4-figure supplement 2. RBM15 protein level in MEG-01 cell lines expressing two shRNA constructs against RBM15 respectively by western blots.

Figure 5. Analysis of RBM15 target genes. (A) Real-time PCR assays for detecting RNA associated with RBM15 in MEG-01 cells by RNA immunoprecipitation assays (RIP) with the RBM15 antibody. The levels of RBM15-associated mRNAs were calculated as mean ± SD from three independent experiments. (B) The distribution of RBM15 binding sites. All the RBM15 target genes were listed in Figure 5-source file 2. (C) Gene ontology (GO) pathway analysis (FDR<0.01) showed pathways associated with genes which
have RBM15 binding sites in introns. (D) GO pathway analysis (FDR <0.01) revealed pathways
associated with genes containing RBM15 binding sites in 3’UTR regions. (E) Differential exon usage
events detected by MISO program. T3UTR: tandem UTR. SE: skipped exon. RI: retention intron. MXE:
mutually exclusive exon usage. ALE: alternative last exon. AFE: alternative first exon. A5SS: alternative
5’ splicing sites. A3SS: alternative 3’ splicing sites. (F) The changes of percentage splice-in events in
different splicing categories when RBM15 is knocked down. (G) MISO plot for skipping of GATA1 exon 2
when RBM15 was knocked down. (H) Isoforms of GATA1fl and GATA1s were detected by PCR using
RNA extracted from MEG-01 cells with or without RBM15 knockdown.

**Figure 5-figure supplement 1.** RBM15 binding to pre-mRNA of genes known important for
hematopoiesis.

**Figure 5-figure supplemental 2.** The RBM15 binding profiles on the c-MPL (panel A) and RUNX1
(panel B) pre-mRNAs.

**Figure 5-figure supplement 3.** The mitochondria biogenesis is regulated by the PRMT1-RBM15
pathway.

**Figure 5-figure supplement 4.** Representative genes detected by MISO and DEXSeq in the RIP group.

**Figure 5-source file 1:** Identification of RNAs associated with RBM15 by RNA immunoprecipitation
assay with anti-RBM15 antibody. Genes related to MK differentiation are highlighted.

**Figure 5-source file 2:** Analysis of gene expression profile changes with RNA-seq data from RBM15
knockdown MEG-01 cells. Genes related to MK differentiation are highlighted.

**Figure 5-source file 3:** Analysis of differential exon usage regulated by RBM15 with RNA-seq data from
RBM15 knockdown MEG-01 cells. Genes related to MK differentiation are highlighted.

**Figure 6.** Methylation of RBM15 controls alternative splicing of genes (*RUNX1, GATA1* and *c-MPL*)
important for megakaryocyte differentiation. (A) Alternative splicing of RUNX1, GATA1, c-MPL in MEG-
01 cells and MEG-01 derived stable cell lines overexpressing RBM15 and PRMT1 V2 or knocking down
RBM15 and PRMT1 V2. The ratios of different isoforms were calculated from real-time PCR assays with
isoform specific primers. At least three independent experiments were performed. P****: <0.01; P***:
<0.05; P**: <0.2 and P*: <0.3 as compared to their respective vector control groups. (B) Time course for alternative splicing of RUNX1, GATA1 and c-MPL in human adult CD34+ cells grown in pro-MK differentiation medium. Three independent experiments were used to calculate the standard deviation. (C) The alternative splicing of GATA1, RUNX1 and c-MPL was measured as ratio change in human adult CD34+ cells treated with DB75 overnight in basic cytokine mix. Three independent experiments were used to calculate the P values.

Figure 6-figure supplement 1. Alternative splicing of GATA1 is regulated by PRMT1 in acute megakaryoblastic leukemia cell lines.

Figure 6-figure supplement 2. Schematic diagram of MPL isoforms.

Figure 6-figure supplement 3. Alternative splicing of c-MPL is measured as the ratios of different isoforms by real-time PCR assays.

Figure 7. RBM15 directly recruits the intron binding splicing factor, SF3B1, for alternative RNA splicing. (A) The interaction between SF3B1 and RBM15 in the context of PRMT1-mediated methylation. RBM15-Flag and RBM15 R578K-Flag expressed from two MEG-01 cell lines with or without DB75 treatment were immunoprecipitated with anti-Flag antibody for detecting interaction with SF3B1 by WB. (B) The endogenous SF3B1 was co-immunoprecipitated with anti-RBM15 antibody in MEG-01 cells expressing inducible shPRMT1. Normal mouse serum was used as a negative control. (C) RBM15 binding profile on GATA1 pre-mRNA based on RIP-seq data. The green peaks were the binding sites for RBM15 and the blue profile was the binding profile for normal IgG. Two biological replicates were used for bioinformatic analysis. The significant peaks were shaded with pink squares. (D) The regions where RBM15 (RIP with RBM15 antibody, left panel) and SF3B1 (RIP with SF3B1 antibody right panel) bound on GATA1 pre-mRNA in MEG-01 cells (solid bar) and RBM15 knockdown MEG-01 cells (open bar) were mapped by real-time PCR assays. The locations of primers on the pre-mRNA of GATA1 were shown on the bottom. Three biological replicates were used to calculate the standard deviations. GAPDH intron 1 was used as negative controls for both antibodies. (E) The regions on c-MPL pre-mRNA, where RBM15 and SF3B1
bound in MEG-01 cell lines expressing shRBM15 (square line) or expressing pLKO vector (solid dot line), were assessed by RIP with RBM15 (left panel) and SF3B1 antibodies (right panel). The locations of primers on the pre-mRNA of c-MPL were shown on the bottom. Three biological replicates were used for standard deviations. (F) A model for RBM15-mediated regulation of alternative RNA splicing. RBM15 and SF3B1 cooperate to produce GATA1fl and low level of RBM15 leads to lower SF3B1 binding and skipping of the exon 2. PRMT1-mediated methylation of RBM15 controls the ubiquitylation of RBM15 by CNOT4, thus controls the balance between proliferation and differentiation in megakaryopoiesis.

**Figure 7-source file 1:** Mass spectrometry analysis of RBM15-associated proteins.

**Figure 1-figure supplement 1.** PRMT1 is overexpressed in AMKL leukemia and associated with short survival rate in AML. (A) PRMT1 is overexpressed in AMKL leukemia compared to other types of AML. Microarray data set (GSE4119) (Bourquin et.al. 2006) was analyzed by NCBI GEO2R tool. Expression values were exported from NCBI GEO2R tool and then re-plotted by GraphPad PRISM 5 software. (B) PRMT1 high expression is correlated with low survival rate in acute myeloid leukemia.

**Figure 1-figure supplement 2.** RBM15 is discovered as a PRMT1 substrate via BPPM. (A) Schematic description of substrate identification with PRMT1 Y39FM48G and Pob-SAM using BPPM technology. (B) HEK293T cells were transfected with either empty vector or the PRMT1 Y39FM48G mutant, followed with treatment of Adox to induce hypomethylation. These cells were then lysed to release the PRMT1 substrates as previously described and the cell lysates were treated with Pob-SAM cofactor. The terminal alkyne-modified substrates were conjugated with the cleavable azido-azo-biotin probe, followed by streptavidin enrichment, sodium dithionite elution and western blotting detection. (C) Western blotting analysis of the pull-down substrate of PRMT1. The eluted targets of PRMT1 were incubated with RBM15 antibody. The pull-down sample from 293T cells transfected with PRMT1 Y39FM48G variant showed significantly higher level of RBM15 compared to the control group. Cell lysates without streptavidin enrichment were assessed by anti-RBM15 western blotting as loading control (Input panel).
**Figure 1-figure supplement 3.** Mapping the methylation site for RBM15. (A) Tandem Mass Spectrometry analysis for Flag-tagged RBM15 purified from 293T cells overexpressing RBM15-Flag. The arrow indicates the modified peptide. (B) Schematic diagram shows domains on RBM15. (C) Dot blot to test the antibody (Mono-R100 from Cell Signaling) recognizing monomethylated RBM15 peptide based on mass spectrometry analysis. Nitrocellulose membrane was spotted with peptides with no modification, with arginine mono-methylated or with arginine asymmetrically dimethylated. The peptide sequences were listed on the right side of the dot blot gel. (D) Dot blot to test the antibody (D4H5 from Cell Signaling) which recognizes asymmetrically dimethylated RBM15 peptide. Peptides were spotted in the same order as in panel C. (E) IP-Western blot for RBM15 protein in Meg-01 cell lines expressing Flag-tagged RBM15 and Flag-tagged RBM15 R578K respectively. The anti-monomethyl arginine antibody was used for immunoprecipitation and the ectopically expressed RBM15 proteins were detected by Flag antibody. (F) IP-Western blotting assays for detecting methylated RBM15 and R3K mutant expressed in 293T cells. RBM15-R3K stands for RBM15 protein with all the arginines in the LYRDRDRD sequence mutated to lysines. (G) The *in vitro* methylation reaction with peptide (LYRDRDRDLY) incubated with purified PRMT1. H4 peptide (20 mer) was used as a positive control. The methylated peptide was detected by the D4H5 dimethyl arginine antibody not by the mono-methyl antibody.

**Figure 1-figure supplement 4.** RBM15 methylation status is further confirmed by a methyl-RBM15 antibody. (A) Dot blot for the anti-methyl-RBM15 antibody. Synthesized RBM15 peptides with different methylation status on arginine 578 were spotted for blotting with the anti-methyl RBM15 antibody. (B to D) RBM15 methylation status was measured by anti-methyl-RBM15 antibody by western blotting. (B) The whole cell extracts from 293T cells expressing PRMT1 were used for western blotting with the anti-methyl RBM15 antibody. Empty vector was used as a control. (C) The whole cell lysates from 293T cells expressing wild type (WT) RBM15 or R578K mutant were used for western blotting. (D) A stable MEG-01 cell line expressing doxycycline (Dox)-inducible shPRMT1 was used to knock down PRMT1. The
expression of methyl-RBM15 was measured by western blotting with anti-methyl RBM15 antibody, RBM15 antibody, PRMT1 antibody and GAPDH antibody respectively.

**Figure 3-figure supplement 1.** Purified proteins used in vitro methylation and ubiquitylation assays. (A) The Flag tagged RBM15 protein was affinity purified by anti-Flag antibody from 293T cells overexpressing FLAG RBM15 protein as shown by Coomassie staining of 10% SDS-PAGE. (B) Affinity purified HA-CNOT4 and HA-PRMT1 proteins were shown by silver staining. Both proteins were produced in 293T cells transfected with pCDNA3-HA-PRMT1 and pCDNA3-HA-CNOT4 respectively. Anti-HA antibody (12Ca5) column was used to purify these proteins. Proteins were eluted by 0.5mg/ml of HA peptide (Sigma) in PBS.

**Figure 3-figure supplement 2.** The efficiency of CNOT4 knockdowns. (A) Real-time PCR assays for CNOT4 in MEG-01 cells expressing shCNOT4. (B) Western blots to show the knockdown efficiencies of two shRBM15 constructs in MEG-01 cells. (C) Using CRISPR to knockdown CNOT4 in 293T cells (A5 is a 293T cell line with only one wild type allele of CNOT4) as shown by real-time PCR on the left and by western blot on the right. RBM15 protein level goes up in CNOT4+/- cells by western blot assays.

**Figure 4-figure supplement 1.** Relative expression levels of PRMT1 isoforms and RBM15 in different hematopoietic lineages derived from mouse and human. (A-C) The relative expression levels of total PRMT1 (including V1 and V2) (A), PRMT1 V2 (B) and RBM15 (C) in different mouse lineages were measured by real-time PCR. The expression level is normalized to GAPDH, then normalized to the level in long-term hematopoietic stem cells (LT-HSC). (D) The surface markers we used to sort mouse lineages. (E) The expression level of PRMT1 in different human hematopoietic lineages. (F) The expression level of RBM15 in different human hematopoietic lineages based on database from HemaExplorer. (G) The abbreviations for the different human hematopoietic lineages used in panels (E) and (F).
**Figure 4-figure supplement 2.** RBM15 protein levels in MEG-01 cell lines expressing two shRNA constructs against RBM15 respectively by western blots.

**Figure 5-figure supplement 1.** RBM15 binding to pre-mRNA of genes known important for hematopoiesis. (A) RBM15 binding peaks on pre-mRNA of CDC42. (B) RBM15 binding sites on pre-mRNA of macroH2A (H2AFZ). (C) RBM15 binding on pre-mRNA of TAL1. (D) RBM15 binding peaks on pre-mRNA of LEF1.

**Figure 5-figure supplement 2.** The RBM15 binding profiles on the c-MPL (A) and RUNX1 (B) pre-mRNAs. The red bar is calculated as significant peaks in bioinformatics analysis.

**Figure 5-figure supplement 3.** The mitochondria biogenesis is regulated by the PRMT1-RBM15 pathway. The mitotracker (MitoTracker deep red FM, Invitrogen) was used to stain active mitochondria in MEG-01 stable cell lines infected with lentivirus vector, lentivirus expressing shRBM15, and lentivirus overexpressing PRMT1 V1 and V2 respectively. The cell nuclei were stained with Hoechst.

**Figure 5-figure supplement 4.** Representative genes detected by MISO and DEXSeq in the genes detected by RIP. In the MISO diagram, the red graph is for MEG-01 cells, and the orange diagrams are for two MEG-01 cell lines expressing two shRBM15 RNAs respectively. (A) TAL1 (aka SCL) skips exon 2 and 3 as detected by DEXSeq and use alternative short 3'UTR after RBM15 was knocked down. TAL1 has the exon 2 (1:47691115-47691561) skipped in RBM15 knockdown cells, which losses protein coding ability for transcript (bottom panel). (B) MacroH2A (H2AFZ) retains intron (4:100870543-100870820) when RBM15 protein level is reduced. (C) RUNX1 has multiple exon usage alteration events as
demonstrated by DEXSeq on the top. The E017 marks the change for generating RUNX1a (E7a is included) when RBM15 is knocked down. The bottom is MISO analysis showing that Exon 6 is skipped to generate a RUNX1 protein without the transcriptional repression region. This isoform was reported (Komeno et.al 2014). (D) CDC42 skips the exon 2a (1:22400587-22400712) or exon 2b (1:22400647-22400712). Although the open reading frame is still intact with the skipping events, the change of 5'UTR might cause changing in efficiency of protein translation.

Figure 6-figure supplement 1. Alternative splicing of GATA1 is regulated by PRMT1 in acute megakaryoblastic leukemia cell lines. P value was calculated from three independent repeats. ****P < 0.01, *** P < 0.05.

Figure 6-figure supplement 2. Schematic diagram of MPL isoforms. (A) A new isoform of MPL (c-MPL-exon9-) (Genebank No. KF964490) was detected in MEG-01 cells. We synthesized cDNA from Meg-01 cells using Verso cDNA synthesis kit (Thermo Scientific) and performed regular PCR with primers as reported (Li et al., 2000). Direct ligation of exon 8 with exon 10 generates a truncated MPL protein as shown below. (B) Schematic diagram of c-MPL isoforms generated by alternative splicing.

Figure 6-figure supplement 3. Alternative splicing of c-MPL is measured as the ratios of different isoforms by real-time PCR assays. The data are the averages from three independent experiments with SD. (A) the ratio between c-MPL72minus-exon9/c-Mpl-exon9+. (B) the ratio between c-MPL-tr/c-MPL-exon 9+. The c-MPL-tr stands for c-MPL isoform without exon 9 and exon 10. We also observed that the ratio of the c-MPL isoform with 72bp missing in the exon 9 (i.e. c-MPL-72minus-exon9+) to c-MPL-exon 9+ mRNA is similarly changed like the ratio of c-MPL-exon 9-/c-MPL-exon 9+ mRNA upon overexpression or knock-down of RBM15 or of PRMT1. We discovered that the ratio of c-MPL-tr (which misses both exon 9 and exon 10) to c-MPL-exon9+ was changed likewise when the RBM15 level is changed as shown in Figure 6.
Supplementary file 1: The real-time PCR primers for human genes.

Supplementary file 2: shRNA sequences for knocking down CNOT4 and RBM15 genes in human cells.


Figure 1. RBM15 is methylated by PRMT1 at R578 in mammalian cells.
Figure 2. PRMT1 V2 isoform destabilizes RBM15 via methylation.
Figure 3. The RBM15 is ubiquitylated in a methylation-dependent manner.
Figure 4. PRMT1 controls the protein level of RBM15 in megakaryocyte maturation.
Figure 5. Analysis of RBM15 target genes.
Figure 6. Methylation of RBM15 controls alternative splicing of genes (RUNX1, GATA1 and c-MPL) important for megakaryocyte differentiation.
Figure 7. RBM15 directly recruits the intron binding splicing factor, SF3B1, for alternative RNA splicing.